An anonymous director reports

CIPHER PHARMACEUTICALS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Cipher Pharmaceuticals Inc. held its annual and special meeting of shareholders earlier today. All matters put forward before shareholders for consideration and approval, as set out in the company's management information circular dated May 10, 2023, were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the reappointment of Ernst & Young LLP as auditor of the company and the change of the location of the company's registered office. A total of 14,351,019 million shares, representing 56.64 per cent of the total shares outstanding, were represented in person or by proxy at the meeting. The detailed results of the vote for the election of directors of Cipher are set out in an attached table.

Craig Mull, the company's interim chief executive officer, wishes to thank Arthur M. Deboeck, Christian Godin and Cathy Steiner for their service to the company, and welcomes new directors Douglas Deeth and Dr. Hubert Walinski to the board.

Mr. Deeth has over 40 years of experience in the pharmaceutical industry, including contract negotiations and complex transactions, and is a founding partner and current managing partner with the law firm Deeth Williams Wall LLP.

Dr. Walinski is currently the chief scientific officer of AIC Global Holdings (since August, 2021) and brings over 13 years of experience across medical and scientific roles in pharmaceuticals and biotechnology at AstraZeneca and Boehringer Ingelheim, both in Canada and globally.

Mr. Mull stated, "I am proud to announce the appointments of Mr. Deeth and Dr. Walinski, who will be able to bring tremendous experience and insight to Cipher's future growth opportunities."

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early-to-late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America.